Search

Your search keyword '"Franks, S. Elizabeth"' showing total 17 results
Start Over Author "Franks, S. Elizabeth"
17 results on '"Franks, S. Elizabeth"'

7. Abstract PO-033: The angiotensin II type 1 receptor blocker telmisartan inhibits the development of transient tumour hypoxia and improves response to ionizing radiation therapy

Author

Wadsworth, Brennan J., primary, Cederberg, Rachel A., additional, Lee, Che-Min, additional, Firmino, Natalie S., additional, Franks, S. Elizabeth, additional, Pan, Jinhe, additional, Colpo, Nadine, additional, Lin, Kuo-Shyan, additional, Benard, Francois, additional, and Bennewith, Kevin L., additional

Published
2020
Full Text
View/download PDF

10. Abstract A50: Interleukin-33 increases ST2+ regulatory T cells and promotes metastatic tumor growth in the lungs in an amphiregulin-dependent manner

Author

Halvorsen, Elizabeth C., primary, Franks, S. Elizabeth, additional, Wadsworth, Brennan J., additional, Harbourne, Bryant T., additional, Cederberg, Rachel A., additional, Steer, Catherine A., additional, Martinez-Gonzalez, Itziar, additional, Calder, Jack, additional, Lockwood, William W., additional, and Bennewith, Kevin L., additional

Published
2020
Full Text
View/download PDF

17. Unique roles of Akt1 and Akt2 in IGF-IR mediated lung tumorigenesis.

Author

Franks SE, Briah R, Jones RA, and Moorehead RA

Subjects
Adenocarcinoma genetics, Adenocarcinoma metabolism, Animals, Apoptosis, Blotting, Western, Cell Transformation, Neoplastic genetics, Cell Transformation, Neoplastic metabolism, Female, Humans, Immunoenzyme Techniques, Lung Neoplasms genetics, Lung Neoplasms metabolism, Male, Mice, Mice, Transgenic, RNA, Messenger genetics, Real-Time Polymerase Chain Reaction, Reverse Transcriptase Polymerase Chain Reaction, Tumor Cells, Cultured, Adenocarcinoma pathology, Cell Transformation, Neoplastic pathology, Lung Neoplasms pathology, Proto-Oncogene Proteins c-akt physiology, Receptor, IGF Type 1 physiology
Abstract

AKT is a serine-threonine kinase that becomes hyperactivated in a number of cancers including lung cancer. Based on AKT's association with malignancy, molecules targeting AKT have entered clinical trials for solid tumors including lung cancer. However, the AKT inhibitors being evaluated in clinical trials indiscriminately inhibit all three AKT isoforms (AKT1-3) and it remains unclear whether AKT isoforms have overlapping or divergent functions. Using a transgenic mouse model where IGF-IR overexpression drives lung tumorigenesis, we found that loss of Akt1 inhibited while loss of Akt2 enhanced lung tumor development. Lung tumors that developed in the absence of Akt2 were less likely to appear as discrete nodules and more frequently displayed a dispersed growth pattern. RNA sequencing revealed a number of genes differentially expressed in lung tumors lacking Akt2 and five of these genes, Actc1, Bpifa1, Mmp2, Ntrk2, and Scgb3a2 have been implicated in human lung cancer. Using 2 human lung cancer cell lines, we observed that a selective AKT1 inhibitor, A-674563, was a more potent regulator of cell survival than the pan-AKT inhibitor, MK-2206. This study suggests that compounds selectively targeting AKT1 may prove more effective than compounds that inhibit all three AKT isoforms at least in the treatment of lung adenocarcinoma.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results